Suggestions
Min Cui
Managing Director at Decheng Capital
Min Cui is a prominent figure in the biotechnology and medical technology investment sector. He is the Founder and Managing Director of Decheng Capital, a venture capital firm he established in December 2011.12 Dr. Cui holds a PhD in Cancer Biology from Stanford University and BS and MS degrees in Molecular Biology from Peking University.12
Career Highlights
- Decheng Capital: Founder and Managing Director (December 2011 - Present)1
- Bay City Capital: Investment Partner (October 2006 - December 2011)1
- Southern Research Institute: Director of Strategic Investment2
- Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals: Co-founder2
Board Memberships
Dr. Cui serves on the boards of several biotechnology companies, including:
- Alpine Immune Sciences (NASDAQ: ALPN)
- Bioheng
- EpimAb Biotherapeutics
- Harton Therapeutics
- ImmPACT Bio
- Mammoth Biosciences
- Mirvie
- Shape Therapeutics2
He has also previously served on the boards of companies such as ARMO BioSciences (acquired by Eli Lilly), China Biologic Products (NASDAQ: CBPO), and GRAIL (acquired by Illumina).2
Expertise
Dr. Cui focuses on partnering with entrepreneurs and building biotechnology and medical technology companies globally.2 His experience spans various fields, including oncology, cardiology, infectious diseases, and inflammatory diseases.2
Additional Information
Dr. Cui is currently a board of trustee at Western University of Health Sciences.2 He was also a co-founder of CNetwork, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America.3
